
bioAffinity Technologies Investor Relations Material
Latest events

Status Update
bioAffinity Technologies

Q1 2025
15 May, 2025

Q4 2024
31 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from bioAffinity Technologies Inc
Access all reports
bioAffinity Technologies Inc. is a biotechnology company focused on addressing the critical need for non-invasive, early-stage cancer diagnosis and targeted cancer treatments. The company's flagship product, CyPath Lung, is a diagnostic test for the early detection of lung cancer. Additionally, the company is involved in research and development efforts aimed at creating targeted diagnostics and therapeutics to combat cancer, leveraging its core porphyrin platform technology. The company is headquartered in is headquartered in San Antonio, Texas, and its shares are listed on the Nasdaq.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
BIAF
Country
🇺🇸 United States